ATE169640T1 - Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore - Google Patents

Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore

Info

Publication number
ATE169640T1
ATE169640T1 AT91919512T AT91919512T ATE169640T1 AT E169640 T1 ATE169640 T1 AT E169640T1 AT 91919512 T AT91919512 T AT 91919512T AT 91919512 T AT91919512 T AT 91919512T AT E169640 T1 ATE169640 T1 AT E169640T1
Authority
AT
Austria
Prior art keywords
polypeptide
prevention
treatment
antibody
malignant tumors
Prior art date
Application number
AT91919512T
Other languages
English (en)
Inventor
Pierre Chambon
Marie-Paule Kieny
Richard Lathe
Mara Hareuveni
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE169640T1 publication Critical patent/ATE169640T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT91919512T 1990-10-23 1991-10-23 Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore ATE169640T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9013101A FR2668064B1 (fr) 1990-10-23 1990-10-23 Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.

Publications (1)

Publication Number Publication Date
ATE169640T1 true ATE169640T1 (de) 1998-08-15

Family

ID=9401474

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91919512T ATE169640T1 (de) 1990-10-23 1991-10-23 Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore

Country Status (11)

Country Link
US (3) US5861381A (de)
EP (1) EP0554344B1 (de)
JP (1) JP3195958B2 (de)
AT (1) ATE169640T1 (de)
CA (1) CA2094705C (de)
DE (1) DE69129989T2 (de)
DK (1) DK0554344T3 (de)
ES (1) ES2121791T3 (de)
FR (1) FR2668064B1 (de)
SG (1) SG96535A1 (de)
WO (1) WO1992007000A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
AU671971B2 (en) * 1991-11-29 1996-09-19 Chiron Corporation Anti-cancer immunotherapeutic vector constructs
FR2751343B1 (fr) * 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
US20040033230A1 (en) * 1997-12-24 2004-02-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000026340A2 (en) * 1998-11-03 2000-05-11 The Penn State Research Foundation Novel nucleic acid molecules encoding opioid growth factor receptors
US6969518B2 (en) * 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7598226B2 (en) * 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
DE19917195B4 (de) * 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
PT1210430E (pt) * 1999-09-08 2006-12-29 Imp Cancer Res Tech Péptidos derivados de muc-1
AU1807401A (en) * 1999-11-30 2001-06-12 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
US20040018181A1 (en) * 2000-09-11 2004-01-29 KUFE Donald W. MUC1 interference RNA compositions and methods derived therefrom
CA2421751C (en) * 2000-09-11 2014-02-11 Donald W. Kufe Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
ATE481640T1 (de) 2000-11-27 2010-10-15 Minerva Biotechnologies Corp Diagnostika, drogenscreening und behandlung für krebs
WO2002058450A2 (en) * 2000-12-22 2002-08-01 Dana-Faber Cancer Institute, Inc. Regulation of cell growth by muc1
NZ528234A (en) 2001-04-02 2006-01-27 Univ Miami Mucin peptide with immunoenhancing properties
US6716627B2 (en) 2001-12-20 2004-04-06 Isis Pharmaceuticals, Inc. Antisense modulation of mucin 1, transmembrane expression
JP3854905B2 (ja) * 2002-07-30 2006-12-06 株式会社 日立ディスプレイズ 液晶表示装置
EP2363410B1 (de) * 2002-11-27 2017-10-11 Minerva Biotechnologies Corporation MUC1-Isoformen
WO2004092339A2 (en) * 2003-04-11 2004-10-28 Ilex Products, Inc. Modulation of muc1 mediated signal transduction
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
DK1697399T3 (en) 2003-12-12 2017-03-06 Government Of The United States Of America As Repr By The Secr Of The Dept Of Health And Human Servi Human cytotoxic t lymphocyte epitope and its agonist epitope from the non-variable number of muc-1 tandem repeat sequences
CA2556729A1 (en) * 2004-02-23 2005-09-09 Genzyme Corporation Muc1 antagonist enhancement of death receptor ligand-induced apoptosis
US20090317414A1 (en) * 2006-07-25 2009-12-24 4G Vaccines Pty Ltd Cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide
US7972870B2 (en) 2007-02-02 2011-07-05 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
US7871784B2 (en) * 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
JP2012515146A (ja) 2009-01-13 2012-07-05 トランジェーヌ、ソシエテ、アノニム 免疫刺激のためのサッカロマイセス・セレビシエのミトコンドリア核酸画分の使用
DK2382474T3 (en) 2009-01-20 2015-04-07 Transgene Sa SOLUBLE ICAM-1 as a biomarker FOR PREDICTION OF THERAPEUTIC RESPONSE
MX2011010061A (es) 2009-03-24 2011-11-18 Transgene Sa Biomarcador para monitorear pacientes.
EP2419728B1 (de) 2009-04-17 2014-01-08 Transgene SA Biomarker für patientenüberwachung
KR20120026526A (ko) 2009-05-12 2012-03-19 트랜스진 에스.에이. 불멸화 조류 세포주 및 그의 용도
AU2010270313B2 (en) 2009-07-10 2014-05-22 Transgene Sa Biomarker for selecting patients and related methods
RU2012106760A (ru) 2009-07-21 2013-08-27 Трансген Са Ферментативная композиция для ферментативного расщепления куриного эмбриона
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
DK3226894T3 (da) 2014-12-01 2019-10-21 Transgene Sa Stabile flydende vacciniavirus-formuleringer
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
EP3256156B1 (de) 2015-02-13 2025-02-12 Transgene Immunotherapeutischer impfstoff und antikörperkombinationstherapie
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
EP3522920A2 (de) 2016-10-10 2019-08-14 Transgene SA Immuntherapeutisches produkt und mdsc-modulator-kombinationstherapie
BR112020018117A2 (pt) 2018-03-07 2020-12-22 Transgene Vírus da pseudovaríola (pcpv), métodos para gerar o pcpv e para amplificar o pcpv, composição, método de tratamento, método para inibir o crescimento de células tumorais, uso ou método e método para induzir ou estimular e/ ou reorientar uma resposta imune

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707438A (en) * 1984-08-22 1987-11-17 Tel Aviv University Immunoassay for breast cancer employing monoclonal antibodies
JPH02501828A (ja) * 1987-01-07 1990-06-21 インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド プローブ
DE10399032I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
SE459115B (sv) * 1987-10-08 1989-06-05 Gas Control Equipment Ab Anordning i ventil foer gasbehaallare
EP0442926A1 (de) * 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptide
JPH02273195A (ja) * 1988-11-17 1990-11-07 Univ Melbourne ヒト多型性上皮ムチンと反応するモノクローナル抗体
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.

Also Published As

Publication number Publication date
DE69129989D1 (de) 1998-09-17
ES2121791T3 (es) 1998-12-16
JPH06502399A (ja) 1994-03-17
US6328956B1 (en) 2001-12-11
EP0554344B1 (de) 1998-08-12
US6203795B1 (en) 2001-03-20
DE69129989T2 (de) 1999-04-08
FR2668064A1 (fr) 1992-04-24
CA2094705C (fr) 2007-05-15
EP0554344A1 (de) 1993-08-11
US5861381A (en) 1999-01-19
DK0554344T3 (da) 1999-05-17
SG96535A1 (en) 2003-06-16
WO1992007000A1 (fr) 1992-04-30
HK1012841A1 (en) 1999-08-06
FR2668064B1 (fr) 1994-12-16
CA2094705A1 (fr) 1992-04-24
JP3195958B2 (ja) 2001-08-06

Similar Documents

Publication Publication Date Title
ATE169640T1 (de) Arzneimittelzusammensetzung zur behandlung oder vorbeugung maligner tumore
NO913211D0 (no) Nytt monoklonalt antistoff mot nytt antigen knyttet til menneske-tumorer.
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
ATE132197T1 (de) Monoklonale antikörper
RU2008128244A (ru) Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2
NZ527283A (en) Modified antibodies and methods of use
Hauck et al. Control of carcinoembryonic antigen gene family expression in a differentiating colon carcinoma cell line, Caco-2
AU7690596A (en) Anti-CD6 monoclonal antibodies and their uses
NZ219338A (en) Monoclonal antibody to non-small cell lung carcinoma, its use, production and antigen
GB2278357B (en) Humanised antibodies directed against A33 antigen
PT812206E (pt) Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
IL187595A (en) Pharmaceutical preparation containing monoclonal antibody - tumors and production
CA2308007A1 (en) Enhancer for antibody to lymphocytic tumors
DE69019410D1 (de) Retinoblastoma-Genprodukt-Antikörper und deren Verwendungen.
AU5752490A (en) A novel tumor associated antigen
AU5790390A (en) A novel tumor associated antigen
ATE95426T1 (de) Humanes karcinom-assoziertes antigen und an dieses antigen bindende antikoerper.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time